Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cancer Research UK, Astellas Partner on Cancer Treatments

Published: Friday, August 08, 2014
Last Updated: Monday, August 11, 2014
Bookmark and Share
The new collaboration will conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer.

Cancer Research UK and its commercial arm, Cancer Research Technology ("CRT"), are to join forces with Astellas Pharma Inc. to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

Certain pancreatic cancers are dependent on autophagy, the process of consuming your own cellular parts for energy, in order to grow. Blocking this pathway may help stop some pancreatic cancers. 

Under the terms of the deal, the first stage aims to identify and then validate the best possible drug targets to block the autophagy pathway in pancreatic cancer cells. This research will be carried out by Professor Kevin Ryan at the Cancer Research UK Beatson Institute and DrSharon Tooze at the Cancer Research UK London Research Institute. Astellas has an exclusive license to progress the most promising candidates through further drug discovery and development, subject to certain milestone and royalty payments to CRT. 

Professor Kevin Ryan, Cancer Research UK scientist based at the Cancer Research UK Beatson Institute, said: "This is an exciting opportunity to develop new drugs for pancreatic cancer where there is an urgent need for new treatments. Research suggests that pancreatic cancer can be dependent on autophagy making it an excellent pathway to target for drug discovery."

Kenji Yasukawa, Ph. D., Senior Vice President and Chief Strategy Officer, Astellas, said "SinceMay 2013, Astellas has invited researchers from around the world to collaborate to increase drug discovery opportunities and expand development pipelines. The aim is to establish links with overseas researchers who have ideas that possess a high level of novelty and creativity. This consortium with Cancer Research UK and CRT is one of the collaborations to be achieved through this global initiative."

New treatments are desperately needed for pancreatic cancer – one of the deadliest forms of cancer. Every year 8,800 people are diagnosed with the disease in the UK but survival rates remain very low, with only three per cent of people diagnosed with pancreatic cancer surviving their disease for five years or more after their diagnosis*.

Dr Keith Blundy, Cancer Research Technology's chief executive officer, said: "In establishing this significant collaboration, the first of its kind between CRT and a Japanese pharmaceutical company, we're bringing together Cancer Research UK's world-leading target validation expertise and Astellas' proven track record on drug development, which we hope will lead to new drugs for pancreatic cancer patients. We're excited to commence this collaboration and look forward to furthering our relationship with Astellas in the future."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Monday, August 17, 2015
Drug Developed in U.K. to Treat Solid Tumors
Cancer Research U.K.'s Drug Development Office; Cancer Research Technology, and Lorus Therapeutics Inc. have partnered to take a new therapy with the potential to treat solid tumors into its first clinical trial.
Friday, November 30, 2012
Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine
IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer
Tuesday, February 16, 2010
Scientific News
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Simplifying Gene Testing Access for Ovarian Cancer Patients
Simplifying access to gene testing for women with ovarian cancer improves treatment choices and could save lives.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
New Skin Cancer Drugs with Surprising Powers
Inserm team synthesizes and developed new drugs for melanoma.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!